Reviews/Dietary Fibre/Fibre improves constipation
Gastrointestinal · FIBRE-GI-02 · v2
Across several independent randomised trials, soluble dietary fibres such as psyllium, inulin and oligofructose improved the symptoms of chronic constipation and made stools softer and better formed [9][10][11][12]. Most trials also found that fibre increased how often people had a bowel movement [4][13][18][5]. The picture is less uniform for frequency specifically: the single largest and best-designed trial found no change in how often people went, even though it confirmed that stools became softer [2]. Some of the trials showing a frequency benefit enrolled generally healthy people with infrequent bowel movements rather than patients formally diagnosed with chronic constipation [4][13][18]. The panel judged that the evidence clearly supports fibre helping constipation symptoms and consistency, with a somewhat weaker and mixed case specifically for stool frequency.
Multiple independent RCTs show soluble/gel-forming fibres improve chronic-constipation symptoms and stool consistency: psyllium and flaxseed reduced ROME III constipation symptoms versus placebo [9][10], and mixed fibre, kiwifruit, prunes and psyllium all improved symptoms in chronically constipated patients [11][12]. Stool frequency rose in most trials: chicory inulin increased frequency versus placebo (median 4.0 vs 3.0 stools/week, p = 0.038) [4], combined inulin data rose from 4.1 to 5.0 per week (p = 0.032) [13], oligofructose was significant at 15 g/day (p = 0.023) [18], and pea-hull fibre plus inulin raised frequency from 1.4 to 1.9 stools/day (P < .05) [5]. Consistency improvements were broad, including a Bristol stool scale increase of 0.95-1.05 across fibre arms in the largest trial [2]. The strongest single result dissents on frequency: the N=250 double-blind RCT found no time-by-group effect on bowel-movement frequency while confirming the consistency benefit [2]. The contested point: The division is on stool frequency specifically: the largest, best-powered, double-blind trial [2] found no group effect on bowel-movement frequency, while the positive frequency signal rests on much smaller trials [4][13][5]. Several of those positive trials also enrolled healthy low-frequency subjects rather than diagnosed chronic-constipation patients [4][13][18], so the frequency half of the claim is both smaller-powered and partly indirect.
All 21 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dietary Fibre, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The single largest and best-powered trial ([2], N=250, double-blind, placebo-controlled) found no group effect on bowel-movement frequency; the positive stool-frequency signal is carried by much smaller trials ([4] n=44, [13] n=30, [5] n=13), so the frequency half of the claim is weaker than the symptom/consistency half.
Population indirectness: several positive stool-frequency trials ([4],[13],[18]) enrolled healthy subjects with 'low stool frequency' or 'irregularity associated with low fiber intake', not clinically diagnosed chronic constipation; generalising their frequency gains to chronic constipation is overreach.
Where it remains uncertain. The single largest double-blind RCT (N=250) found no effect on bowel-movement frequency while confirming improved consistency [2], and several frequency-positive trials studied non-clinical low-frequency populations [4][13][18].
Aleatory
The positive frequency signal comes from small trials ([4] n=44, [13] combined n=16-30, [5] n=13), where chance variation around the frequency estimate is wide.
Epistemic
The best-powered double-blind RCT [2] found no bowel-movement-frequency effect, so whether fibre reliably raises frequency in true chronic constipation remains unresolved.
Inferential
[4], [13] and [18] enrolled healthy subjects with low stool frequency or fibre-intake irregularity, not diagnosed chronic constipation, so transferring their frequency gains to the claim's population is an inferential step the corpus does not fully justify.
The load-bearing papers from a corpus of 21, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest, best-powered trial: null on stool frequency but positive on consistency; tempers the frequency half of the claim.
“No time-by-group effect was observed for bowel movement frequency (BMF), Bristol stool scale score (BSS), and degree of defecation straining (DDS), while BSS showed mean increases of 0.95-1.05 in group A to D (all P < 0.05), but not significantly changed in placebo ( P = 0.170)”
Panel auditInternal validity: high · scope of inference: Effect of several dietary fibres on bowel frequency and stool form in adults with functional constipation over 4 weeks.Key limitations: no time-by-group effect on frequency · benefit limited to stool consistency · short duration
Placebo-controlled crossover demonstrating a significant stool-frequency increase in constipated subjects.
“Consumption of Orafti® Inulin significantly increased stool frequency compared to placebo (median 4.0 [IQR 2.5-4.5] versus 3.0 [IQR 2.5-4.0] stools/week, p = 0.038)”
Panel auditInternal validity: high · scope of inference: Effect of 12 g/day chicory inulin on stool frequency in healthy subjects with constipation.Key limitations: small sample · healthy volunteers with constipation rather than clinically referred patients
Fibre raised stool frequency, albeit small, uncontrolled, in a CKD population.
“Stool frequency increased from 1.4 ± 0.2 stools/day during control to 1.9 ± 0.3 stools/day during both fiber periods (P < .05)”
Panel auditInternal validity: low · scope of inference: Effect of supplemental fibre on stool frequency in CKD patients, who were not selected for chronic constipation.Key limitations: very small sample · no randomised control arm · CKD not constipation population
Laxative dose decreased numerically in the fibre groups but the changes were not significant versus placebo.
Panel auditInternal validity: low · scope of inference: Effect of increased fibre on laxative requirement and bowel function in peritoneal dialysis patients.Key limitations: non-significant laxative change · dialysis-specific population · poor adherence in diet arm
4 of 21 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus consistently supports fibre improving chronic constipation and, in most but not all trials, stool frequency, with the pivotal large RCT dissenting on frequency, warranting a Likely rather than Established verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Adequately powered frequency RCT in diagnosed chronic constipation. The frequency half of the claim rests on small trials while the only large trial [2] was null on frequency, leaving the central question unresolved. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large, double-blind, placebo-controlled RCT in ROME-diagnosed chronic-constipation patients with complete-spontaneous-bowel-movement frequency as the primary endpoint.
Open question: Does soluble dietary fibre increase bowel-movement frequency in formally diagnosed chronic-constipation patients when tested at scale? Why it is still open: The largest double-blind RCT [2] found no time-by-group effect on bowel-movement frequency, while the positive frequency signal comes from small trials [4][13][5].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19